PE03932000A1 - Stable particles of crystalline organic compounds - Google Patents

Stable particles of crystalline organic compounds

Info

Publication number
PE03932000A1
PE03932000A1 PE00014199A PE00014199A PE03932000A1 PE 03932000 A1 PE03932000 A1 PE 03932000A1 PE 00014199 A PE00014199 A PE 00014199A PE 00014199 A PE00014199 A PE 00014199A PE 03932000 A1 PE03932000 A1 PE 03932000A1
Authority
PE
Peru
Prior art keywords
particles
uniform
size
particle
organic compounds
Prior art date
Application number
PE00014199A
Other languages
Spanish (es)
Inventor
Juan Angeles Uribe
Gyves Aurelio De
Abraham Gomez
Original Assignee
Savoir John Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US09/030,388 priority Critical patent/US6287693B1/en
Application filed by Savoir John Claude filed Critical Savoir John Claude
Publication of PE03932000A1 publication Critical patent/PE03932000A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21853984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE03932000(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989Microcapsule with solid core [includes liposome]

Abstract

CARACTERIZADO POR: PROPORCIONAR PARTICULAS ESTABLES FORMADAS DE UNO O MAS COMPUESTOS ORGANICOS MOLECULARES ALOTROPICOS, DICHAS PARTICULAS COMPRENDEN ADICIONALMENTE DE EXCIPIENTES ESTABILIZADORES Y AMORTIGUADORES. Characterized by: STABLE PARTICLE FORMED TO PROVIDE ONE OR MORE ORGANIC COMPOUNDS MOLECULAR allotropic, said particles comprise ADDITION OF EXCIPIENTS STABILIZERS AND SHOCKS. LAS PARTICULAS SON SOMETIDAS A UN PROCESO DE CRISTALIZACION DE ESTADO SOLIDO, EL CUAL ES EFECTUADO EXPONIENDO LAS PARTICULAS A UNA ATMOSFERA CONTROLADA Y SATURADA CON LOS VAPORES DE UN SOLVENTE O SOLVENTES, EN DICHA ATMOSFERA EL COMPUESTO ORGANICO DE LA PARTICULA RECUPERADA POSEE UNA ESTRUCTURA CRISTALINA UNIFORME. The particles are subjected to a crystallization process SOLID STATE, WHICH IS PERFORMED EXPOSING PARTICLES TO A CONTROLLED ATMOSPHERE AND SATURATED WITH FUMES a solvent or solvents, in that atmosphere COMPOUND ORGANIC PARTICLE recovered has a crystalline structure UNIFORM . LA PARTICULA RECUPERADA TIENE ALTERACIONES NO MAYORES DEL 10% EN SUS DIMENSIONES, CON ALTO GRADO DE ESTABILIDAD PARA EL ALMACENAMIENTO, MAYOR UNIFORMIDAD DE TAMANO Y FORMA, PERFILES DE DISOLUCION MAS UNIFORMES Y PREDECIBLES. PARTICLE HAS RECOVERED ALTERATIONS not exceed 10% in size, with high storage stability, more uniform size and shape, dissolution profiles more uniform and predictable. LAS PARTICULAS ESTAN HECHAS PREFERIBLEMENTE DE MICROESFERAS ESTABLES EN FLUIDOS ACUOSOS CUYO TAMANO ES SELECCIONADO PARA LA ADMINISTRACION USANDO UNA AGUJA HIPODERMICA O PARA ASEGURAR UNA TASA DE DISOLUCION DESEADA The particles are preferably made STABLE microsphere aqueous fluids whose size is chosen for administration using a hypodermic needle or to ensure dissolution rate DESIRED
PE00014199A 1998-02-25 1999-02-17 Stable particles of crystalline organic compounds PE03932000A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/030,388 US6287693B1 (en) 1998-02-25 1998-02-25 Stable shaped particles of crystalline organic compounds

Publications (1)

Publication Number Publication Date
PE03932000A1 true PE03932000A1 (en) 2000-05-04

Family

ID=21853984

Family Applications (1)

Application Number Title Priority Date Filing Date
PE00014199A PE03932000A1 (en) 1998-02-25 1999-02-17 Stable particles of crystalline organic compounds

Country Status (32)

Country Link
US (7) US6287693B1 (en)
EP (4) EP1056444B1 (en)
JP (2) JP4885357B2 (en)
CN (2) CN1146407C (en)
AR (3) AR018107A1 (en)
AT (2) AT345779T (en)
AU (1) AU747779B2 (en)
BR (1) BR9908156A (en)
CA (1) CA2319176C (en)
CY (1) CY1118522T1 (en)
CZ (1) CZ301042B6 (en)
DE (2) DE69934099T2 (en)
DK (3) DK2085075T3 (en)
EE (1) EE05019B1 (en)
ES (3) ES2275334T3 (en)
HK (2) HK1036017A1 (en)
HU (1) HU0101271A3 (en)
ID (1) ID26523A (en)
IL (2) IL137970D0 (en)
MY (1) MY138375A (en)
NO (1) NO331804B1 (en)
NZ (1) NZ505987A (en)
PE (1) PE03932000A1 (en)
PL (1) PL196369B1 (en)
PT (1) PT2085075T (en)
RU (1) RU2225708C2 (en)
SA (1) SA740B1 (en)
TR (1) TR200002462T2 (en)
TW (1) TWI256308B (en)
UA (1) UA73470C2 (en)
WO (1) WO1999043304A1 (en)
ZA (1) ZA9901058B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP2314591B1 (en) * 2002-05-16 2014-06-18 Janssen R&D Ireland Pseudopolymorphic forms of a hiv protease inhibitor
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
CA2528545C (en) * 2003-06-13 2014-08-12 John Claude Savoir Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
BRPI0417360A (en) * 2003-12-04 2007-03-13 Pfizer Prod Inc Method for the preparation of pharmaceutical multiparticulate
PT2074989E (en) * 2004-02-23 2014-02-06 Euro Celtique Sa Abuse resistance opioid transdermal delivery device
US20080200682A1 (en) * 2005-06-17 2008-08-21 Basf Aktiengesellschaft Process of Producing Bleach Boosters
US20090246265A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
EP2272519A4 (en) * 2008-04-14 2011-04-27 Posi Visionary Solutions Llp Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
FR2939326B1 (en) * 2008-12-10 2011-04-01 Univ Joseph Fourier Method and control device for crystallization.
CA2773521C (en) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
UY33103A (en) * 2009-12-15 2011-07-29 Techsphere S A De C V Parenteral pharmaceutical formulation in suspension, sustained release, low and ultra low dose of hormone therapy in climacteric syndrome
KR101708528B1 (en) * 2010-03-19 2017-02-20 다이이찌 산쿄 가부시키가이샤 Crystal of diamine derivative and method of producing same
KR101314126B1 (en) 2011-03-11 2013-10-04 서울대학교산학협력단 Polyhedral drug delivery system
US9351924B2 (en) 2011-03-11 2016-05-31 Snu R&Db Foundation Drug delivery system including laminated structure
US20150133421A1 (en) 2012-11-21 2015-05-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584A4 (en) 2011-11-23 2015-12-23 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
MX2014015900A (en) 2012-06-18 2015-07-17 Therapeuticsmd Inc Progesterone formulations.
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
ITUB20153652A1 (en) * 2015-09-16 2017-03-16 Fatro Spa Microspheres containing macrocyclic lactones antielminitici
KR20180126582A (en) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 Steroid hormone pharmaceutical compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447362A (en) 1945-11-01 1948-08-17 Rca Corp Production of crystals
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US4230621A (en) * 1978-05-01 1980-10-28 E. R. Squibb & Sons, Inc. Steroid derivatives and their use in radioimmunoassays
DE2843963C2 (en) * 1978-10-09 1988-02-18 Merck Patent Gmbh, 6100 Darmstadt, De
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
DE3049196C2 (en) 1980-12-24 1989-02-02 Bayer Ag, 5090 Leverkusen, De
US4447426A (en) * 1982-01-18 1984-05-08 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
JPS6327049B2 (en) 1982-02-22 1988-06-01 Ichimaru Fuarukosu Kk
DE3213025C2 (en) 1982-04-02 1997-06-12 Fischer Karl Ind Gmbh A process for the postcondensation of polycondensates
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
JPH0714625B2 (en) 1987-03-30 1995-02-22 呉羽化学工業株式会社 High crystallinity polyarylene - Renchioe - ether moldings
US4897307A (en) 1987-08-11 1990-01-30 The Dow Chemical Company Process for the solvent-induced crystallization of amorphous poly(etheretherketone)-type polymers and the article formed thereby
DE3850384D1 (en) 1987-09-28 1994-07-28 Asahi Chemical Ind A process for preparing crystalline aromatic polycarbonate thus prepared and aromatic polycarbonates.
US4919899A (en) 1988-02-29 1990-04-24 Herrmann Frederick T Crystal growth apparatus
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
IT1230566B (en) 1988-10-17 1991-10-28 Vectorpharma Int poorly soluble drugs supported on polymer substances in a form capable of increasing speed 'dissolution
US5360478A (en) 1989-10-16 1994-11-01 Phasex Corporation Gas anti-solvent recrystallization process
US5686092A (en) 1992-11-24 1997-11-11 Alkermes Controlled Therapeutics Inc. Ii Growth promoters for animals
FR2663224B1 (en) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa parenteral dosage form.
FR2663223B1 (en) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab parenteral dosage form.
JPH04305226A (en) 1991-01-25 1992-10-28 Senichi Masuda Method for decreasing nox in gas
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (en) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble Substances
US5391810A (en) 1991-05-23 1995-02-21 Ajinomoto Co., Inc. Method of crystallizing α-L-aspartyl-L-phenylalanine methyl ester
DE4130173A1 (en) 1991-09-11 1993-03-18 Bayer Ag Pharmaceutical compositions with a specific crystal modification of 1,4-dihydro-2,6-dimethyl-4- (3-nitrophenyl) -3,5-pyridinedicarboxylic acid isopropyl- (2-methoxyethyl) ester
DE4218929C1 (en) 1992-06-10 1993-09-09 Deutsche Bundesbahn, Vertreten Durch Das Bundesbahn-Zentralamt Minden (Westf.), 4950 Minden, De
US5290913A (en) 1992-10-08 1994-03-01 Carrier Vibrating Equipment, Inc. Method and apparatus for the heat treatment of material
US5558678A (en) 1992-11-13 1996-09-24 Karl Fischer Industrieanlagen Gmbh Process and apparatus for continuous crystallization of plastic granules
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US5409605A (en) * 1993-08-05 1995-04-25 Chemical Lime Company Apparatus and method for treating waste sludge
JPH0757558A (en) * 1993-08-09 1995-03-03 Showa Electric Wire & Cable Co Ltd Heat-resistant insulated electric wire
SE9302777D0 (en) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning Substances
DE4440337A1 (en) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug administration than systems with increased saturation solubility and dissolution rate
US5849651A (en) * 1995-06-01 1998-12-15 Kabushiki Kaisha Toshiba Reversible thermal recording medium
JPH09227558A (en) * 1996-02-28 1997-09-02 Fujisawa Pharmaceut Co Ltd Stable crystal of thiazole compound and its production
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
JP2000143832A (en) 1998-11-10 2000-05-26 Toppan Printing Co Ltd Film or sheet having high rigidity

Also Published As

Publication number Publication date
HU0101271A2 (en) 2001-09-28
DE69934099T2 (en) 2007-06-21
DE69934099D1 (en) 2007-01-04
PL343170A1 (en) 2001-07-30
ID26523A (en) 2001-01-11
ES2609284T3 (en) 2017-04-19
US6663895B2 (en) 2003-12-16
CZ20003047A3 (en) 2000-11-15
DK1056444T3 (en) 2007-03-12
EP1772141B1 (en) 2009-04-01
CN100528140C (en) 2009-08-19
IL137970A (en) 2006-10-05
US7427413B2 (en) 2008-09-23
HK1036017A1 (en) 2005-02-25
ZA9901058B (en) 1999-08-11
NO20004241L (en) 2000-08-24
UA73470C2 (en) 2000-12-15
CN1524608A (en) 2004-09-01
ES2324366T3 (en) 2009-08-05
EP2085075A1 (en) 2009-08-05
DK1772141T3 (en) 2009-07-20
CA2319176A1 (en) 1999-09-02
EP1056444A1 (en) 2000-12-06
US6737081B2 (en) 2004-05-18
CN1146407C (en) 2004-04-21
JP2002504507A (en) 2002-02-12
WO1999043304A1 (en) 1999-09-02
US20030147964A1 (en) 2003-08-07
PT2085075T (en) 2017-01-04
JP2011241220A (en) 2011-12-01
US20020168395A1 (en) 2002-11-14
HU0101271A3 (en) 2002-10-28
MY138375A (en) 2009-05-29
RU2225708C2 (en) 2004-03-20
CZ301042B6 (en) 2009-10-21
US6638536B2 (en) 2003-10-28
AR018107A1 (en) 2001-10-31
EE200000492A (en) 2002-02-15
IL137970D0 (en) 2001-10-31
EP2319497A1 (en) 2011-05-11
AR077167A2 (en) 2011-08-10
US6537580B1 (en) 2003-03-25
AR077168A2 (en) 2011-08-10
EE05019B1 (en) 2008-06-16
EP1772141A1 (en) 2007-04-11
NO331804B1 (en) 2012-04-10
CY1118522T1 (en) 2017-07-12
US20030191101A1 (en) 2003-10-09
NO20004241D0 (en) 2000-08-24
NZ505987A (en) 2003-07-25
TR200002462T2 (en) 2000-11-21
SA740B1 (en) 2006-04-26
PL196369B1 (en) 2007-12-31
AT345779T (en) 2006-12-15
HK1155384A1 (en) 2013-05-16
EP1056444B1 (en) 2006-11-22
DK2085075T3 (en) 2017-01-23
EP2319497B1 (en) 2012-08-22
EP2085075B1 (en) 2016-09-28
DE69940684D1 (en) 2009-05-14
BR9908156A (en) 2000-10-31
TWI256308B (en) 2006-06-11
US6528094B1 (en) 2003-03-04
US6287693B1 (en) 2001-09-11
AT427102T (en) 2009-04-15
ES2275334T3 (en) 2007-06-01
US20040166164A1 (en) 2004-08-26
AU747779B2 (en) 2002-05-23
JP4885357B2 (en) 2012-02-29
CA2319176C (en) 2007-09-11
CN1291887A (en) 2001-04-18
AU2293699A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
US3621321A (en) Electroluminescent device with light emitting aromatic, hydrocarbon material
DE1770204B1 (en) Adriamycin and its salts with pharmacologically acceptable inorganic and organic acids, as well as therapeutic compositions containing these
Maslak Fragmentations by photoinduced electron transfer. Fundamentals and practical aspects
GB1104497A (en) Recovery of spent etchants
ES2179552T3 (en) Deposit anhydrous drug for electrolytic transdermal device.
ES2003139A6 (en) Process for preparing beads for obtaining products of controlled drug release.
ES8707666A1 (en) Procedure for obtaining a graft composition for controlled release of macromolecules
MX9301716A (en) A pharmaceutical composition having a defined lipid system.
CY1115685T1 (en) PHARMACEUTICAL COMPOSITION FOR treating afpnias through ypoglossias ADMINISTRATION
AR013854A1 (en) PROCESS TO MAINTAIN dispersion of a powdery composition IN TIME
BR9702362A (en) New fomrulações net stable based on paracetamol and their method of preparation.
PE07652008A1 (en) Pharmaceutical dosage forms
ES8600239A1 (en) A process for preparing 4-aminoalkyl-2 (3h) -indolonas
ES2056845T3 (en) Process for producing polymers of olefins and catalyst used in the.
NO331721B1 (en) Thiophene derivatives as antiviral agents for flavivirusinfeksjon, pharmaceutical compositions, using thiophene derivatives for the preparation of medicament and methods feed for the production of compounds.
AR061992A1 (en) Improvements regarding nanodispersions
CY1107259T1 (en) Azalide antibiotic for local thepapeia eye infections
PE13632001A1 (en) Peptide analogs similar to glucagon-1
CY1110521T1 (en) Substituted indoles of the configuration of nfkb-ACTIVITY
ES2177637T3 (en) Drugs for the treatment of restenosis, comprising nitric oxide-releasing polymers.
CL2003002786A1 (en) Lyophilized composition comprising i) an epothilone and ii) mannitol or a cyclodextrin and lyophilized composition comprising reconstituted with the solvent, useful as cytotoxic in tumor treatment.
ES2178449T3 (en) Method of producing a flexible fabric for implanting dehydrated.
EA200900184A1 (en) 4-amino-4-oksobutanoilovye peptides as inhibitors of viral replication
UY28067A1 (en) Depot formulations of controlled release
AR018783A1 (en) Injection syringe including device and method for the preparation of injection

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term